Pancreatic Cancer Research

ResearcherUniversity of British ColumbiaNo recent work listed

Shilpa Patil

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8412-362X; OpenAlex author ID A5044355879. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 9

  1. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Co-author DOI 10.1016/j.cmet.2023.10.003↗
  2. Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes. Co-author DOI 10.1159/000520946↗
  3. TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. First author DOI 10.3390/cancers14143451↗
  4. HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. First author DOI 10.3390/cancers13246163↗
  5. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Co-author DOI 10.3390/cells10123463↗
  6. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗
  7. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  8. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Co-author DOI 10.3390/cells8060563↗
  9. Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models. Co-author DOI 10.3791/56979↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisabeth Heßmann · 7 shared papers, 2018–2022 · strength 0.73
  2. Albrecht Neeße · 6 shared papers, 2018–2022 · strength 0.60
  3. Volker Ellenrieder · 6 shared papers, 2018–2022 · strength 0.60
  4. Shiv K. Singh · 4 shared papers, 2019–2022 · strength 0.43
  5. Janel L. Kopp · 2 shared papers, 2022–2023 · strength 0.41
  6. Lennart Versemann · 3 shared papers, 2020–2022 · strength 0.34
  7. Jochen Gaedcke · 3 shared papers, 2019–2021 · strength 0.28
  8. Robert G. Goetze · 3 shared papers, 2018–2019 · strength 0.26
  9. Xin Wang · 2 shared papers, 2020–2021 · strength 0.22
  10. Steven A. Johnsen · 2 shared papers, 2019–2020 · strength 0.16
  11. Jeffrey S.H. Lin · 1 shared paper, 2023 · strength 0.14
  12. James D. Johnson · 1 shared paper, 2023 · strength 0.14
  13. David F. Schaeffer · 1 shared paper, 2023 · strength 0.14
  14. Anni M.Y. Zhang · 1 shared paper, 2023 · strength 0.14
  15. Katharina M. Ewers · 1 shared paper, 2021 · strength 0.13
  16. Matthias Dobbelstein · 1 shared paper, 2021 · strength 0.13
  17. Markus Schirmer · 1 shared paper, 2019 · strength 0.09
  18. Jin‐San Zhang · 1 shared paper, 2020 · strength 0.08
  19. Laura Urbach · 1 shared paper, 2020 · strength 0.08
  20. Melanie S. Patzak · 1 shared paper, 2019 · strength 0.08
  21. Thomas Knösel · 1 shared paper, 2019 · strength 0.08
  22. Feda H. Hamdan · 1 shared paper, 2019 · strength 0.08
  23. Christian P. Pilarsky · 1 shared paper, 2019 · strength 0.08
  24. Frances M. Richards · 1 shared paper, 2019 · strength 0.08
  25. Duncan Ian Jodrell · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.